What is BioLoomics?
BioLoomics operates at the intersection of advanced laboratory research and pharmaceutical innovation, specializing in the development of Super-ADCs, or Antibody-Drug Conjugates. These complex therapeutic agents represent a significant leap forward in targeted drug delivery, designed to enhance efficacy while minimizing systemic toxicity. Central to their operational model is the application of Directed Evolution, a sophisticated methodology that mimics natural selection to optimize biological molecules for specific clinical outcomes.
The company serves a diverse portfolio of clients within the biotechnology and pharmaceutical sectors, providing the technical infrastructure necessary to navigate the complexities of modern drug discovery. By prioritizing rigorous scientific inquiry and scalable research frameworks, BioLoomics maintains a distinct competitive advantage in the life sciences market.
How much funding has BioLoomics raised?
BioLoomics has raised a total of $8.7M across 1 funding round:
Angel/Seed
$8.7M
Angel/Seed (2023): $8.7M with participation from Horizons Ventures, BoxOne Ventures, and Innovation Endeavors
Key Investors in BioLoomics
Horizons Ventures
A venture capital firm specializing in deep science and technology, dedicated to supporting transformative projects that aim to improve humanity's future.
BoxOne Ventures
A firm operating within the financial services and transaction processing sector, providing strategic capital to emerging growth companies.
Innovation Endeavors
An early-stage venture capital firm that invests in visionary founders and transformational technologies, with a specific focus on the intersection of data, computation, and advanced engineering.
What's next for BioLoomics?
With the successful closure of this major enterprise-level funding, BioLoomics is poised to transition from its current research-heavy phase into a more robust scaling operation. The strategic roadmap likely includes the expansion of its Directed Evolution programs and the potential for new collaborative ventures with global pharmaceutical partners.
The infusion of capital will be instrumental in scaling the company's internal R&D capabilities, allowing for the rapid iteration of its Super-ADC pipeline. As the firm continues to refine its proprietary technologies, the focus will shift toward clinical validation and the establishment of long-term commercial partnerships, ensuring that their innovative therapeutic solutions reach the market with maximum impact.
